You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Patent: 10,703,800


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,703,800
Title:Cell culture medium
Abstract: Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol.
Inventor(s): Leber; Christopher T. (San Diego, CA), Shen; Michael W.Y. (San Diego, CA), Tao; Yiwen (San Diego, CA), Murray, IV; Hugh Eugene (San Diego, CA)
Assignee: LA JOLLA BIOLOGICS, INC. (San Diego, CA)
Application Number:15/498,221
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Patent Landscape for United States Patent 10,703,800

Introduction

Understanding the patent landscape, particularly for a specific patent like United States Patent 10,703,800, involves a detailed analysis of several key aspects, including the patent's claims, the legal framework governing patent eligibility, and the current trends and challenges in patent law.

Patent-Eligible Subject Matter

Overview of Section 101 of the Patent Act

The foundation of patent eligibility in the United States is laid out in Section 101 of the Patent Act (35 U.S.C. §101), which defines patentable subject matter as "any new and useful process, machine, manufacture, or composition of matter"[1].

Judicially Developed Exceptions

The Supreme Court has established implicit exceptions to patent-eligible subject matter, including "laws of nature, natural phenomena, and abstract ideas" when claimed as such. These exceptions have been refined through several landmark cases, such as Bilski v. Kappos and Mayo Collaborative Servs. v. Prometheus Labs.[1].

The Alice/Mayo Test

Determining Patent Eligibility

The Alice Corp. v. CLS Bank International decision introduced a two-step test to determine whether a patent claim is eligible under Section 101:

  1. Step One: Determine if the claim is directed to an abstract idea, law of nature, or natural phenomenon.
  2. Step Two: If the claim is directed to an ineligible concept, assess whether the claim elements, both individually and as an ordered combination, contain an inventive concept that "transforms the nature of the claim" into a patent-eligible application[1].

Patenting Algorithms

Criteria for Patentability

For an algorithm to be patentable, it must meet specific criteria:

  • Novelty: The algorithm must represent a new idea not previously disclosed.
  • Non-obviousness: The algorithm must not be an evident solution to someone skilled in the field.
  • Tied to a Technological Implementation: The algorithm must be aligned with practical utility and technological enhancement to qualify as patentable subject matter[2].

Supreme Court Precedents

Cases like Alice Corp. v. CLS Bank International and Bilski v. Kappos have set strong precedents that abstract ideas implemented through computers or mere mathematical formulas without practical application are not patentable. This emphasizes the need for algorithms to be tied to specific technological innovations or applications[2].

The Patent Application Process

Preparation and Examination

Submitting a patent application involves thorough research on existing patents to ensure originality, detailed documentation of the algorithm’s functionality, and clear claims defining the patent boundaries. Collaboration with a patent attorney is crucial for drafting technical descriptions and claims that meet USPTO guidelines. The examination process by USPTO patent examiners includes reviewing prior art to verify novelty and addressing any objections or requests for additional information[2].

USPTO Guidance and Recent Developments

2019 Guidance on AI-Related Inventions

The USPTO issued new guidance in 2019 to clarify how to apply the Alice/Mayo framework, particularly for AI-related inventions. This guidance was incorporated into the Manual of Patent Examining Procedure and has been perceived as lowering Section 101 barriers to patentability, leading to an increase in the allowance rate for AI-related patent applications. However, this guidance is not binding on courts when issued patents are challenged in litigation[1].

Use of AI Tools in Patent Applications

Recent guidance from the USPTO also addresses the use of AI tools in patent applications. If an AI tool is material to patentability, its use must be disclosed to the USPTO. This includes assessing whether contributions made by AI systems rise to the level of inventorship and ensuring the accuracy of factual assertions in documents prepared with AI assistance[5].

Stakeholder Views and Impact on Innovation

Debate on the Alice/Mayo Framework

Stakeholders have varying views on whether the Alice/Mayo framework has positively or negatively affected the patent system’s ability to encourage innovation. Some argue it has hindered investment in technology, while others see it as necessary to prevent the patenting of abstract ideas that do not contribute to technological progress[1].

Case Studies and Legal Precedents

Significant Cases

Understanding past legal precedents is crucial for navigating the patent landscape. Cases like Alice Corp. v. CLS Bank International and Bilski v. Kappos have significantly shaped the criteria for what constitutes a patentable algorithm. These decisions emphasize the importance of tying abstract ideas to specific technological implementations[2].

Patent Search and Validation

Importance of Thorough Searches

Conducting thorough patent searches is essential to determine the novelty and non-obviousness of an invention. This involves searching global patent publications and non-patent literature to identify references that disclose similar inventions and to evaluate the strength of the invention[3].

Trends in Patent Activity

USPTO Patent Activity

The USPTO data shows trends in patent activity, with a significant increase in electrical engineering patents between 2000 and 2018, driven by advancements in information and communication technologies (ICT). This highlights the dynamic nature of the patent landscape and the importance of staying updated with technological trends[4].

Key Takeaways

  • Patent Eligibility: The patentability of an invention, including algorithms, hinges on meeting the criteria set forth in Section 101 of the Patent Act and passing the Alice/Mayo test.
  • Technological Implementation: Algorithms must be tied to specific technological innovations or applications to be patentable.
  • USPTO Guidance: Recent guidance from the USPTO has clarified the application of the Alice/Mayo framework, particularly for AI-related inventions.
  • Use of AI Tools: The use of AI tools in patent applications must be disclosed and verified to ensure compliance with patent laws.
  • Stakeholder Views: The impact of the Alice/Mayo framework on innovation is debated, with varying views on its effectiveness in encouraging technological progress.

FAQs

Q: What are the main criteria for an algorithm to be patentable?

A: An algorithm must be novel, non-obvious, and tied to a specific technological implementation or practical application to be patentable[2].

Q: How does the Alice/Mayo test affect patent eligibility?

A: The Alice/Mayo test determines if a claim is directed to an abstract idea and if it contains an inventive concept that transforms the nature of the claim into a patent-eligible application[1].

Q: What is the significance of the 2019 USPTO guidance on AI-related inventions?

A: The 2019 guidance clarified how to apply the Alice/Mayo framework for AI-related inventions, leading to an increase in the allowance rate for such patent applications[1].

Q: How should the use of AI tools be disclosed in patent applications?

A: The use of AI tools must be disclosed if it is material to patentability, and practitioners must verify the accuracy of factual assertions made with AI assistance[5].

Q: What is the current trend in USPTO patent activity?

A: There has been a significant increase in electrical engineering patents, driven by advancements in ICT, indicating a dynamic and technology-driven patent landscape[4].

Sources

  1. Congressional Research Service, "Patent-Eligible Subject Matter Reform: An Overview," January 3, 2024.
  2. Patent Lawyer, "Can You Patent an Algorithm? Understanding Legal Boundaries," June 20, 2024.
  3. Clarivate, "Patent Search Services - Patent Validity Search," 2024.
  4. National Science Foundation, "Invention: U.S. and Comparative Global Trends," January 15, 2020.
  5. Buchanan Ingersoll & Rooney PC, "U.S. Patent Office Issues Additional Guidance on Use of AI Tools," April 15, 2024.

More… ↓

⤷  Subscribe

Details for Patent 10,703,800

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 December 22, 1994 10,703,800 2036-04-26
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 10,703,800 2036-04-26
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 December 10, 1997 10,703,800 2036-04-26
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 May 12, 1998 10,703,800 2036-04-26
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 January 02, 2003 10,703,800 2036-04-26
Swedish Orphan Biovitrum Ab (publ) SYNAGIS palivizumab For Injection 103770 June 19, 1998 10,703,800 2036-04-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.